Actelion Pharmaceuticals Ltd / Actelion to discuss its specialty immunology pipeline compounds . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Dear member of the investment community
Actelion has announced that it is accelerating its clinical development efforts in the field of immunological disorders. An investor conference call & webcast will be held at 13.00 hrs, CEST to offer the opportunity to discuss the rational for this strategic decision.
Date/Time:
16 April 2015 | 13.00 hrs - 14.00 hrs | Basel (CEST) |
12.00 hrs - 13.00 hrs | UK (BST) | |
07.00 a.m. - 08.00 a.m. | US (EDT) |
Conference Call Connect #:
Dial-in participants should start calling the number below 10-15 minutes before the conference is due to start.
Dial: | Europe: | +41 (0) 44 580 00 77 | |||
UK: | +44 (0) 203 367 94 59 | ||||
US: | +1 866 907 59 28 |
Participant's mode:
Listen-Only with possibility to open individual lines during Q&A session.
Participants will be asked for their Name and Company.
Webcast Access:
Webcast participants should visit the Actelion website http://www.actelion.com:
http://www.actelion.com/ 10-15 minutes before the conference is due to start.
Participant's mode:
Listen-Only
Webcast Replay:
The archived Investor Webcast will be available for replay through http://www.actelion.com:
http://www.actelion.com// approximately 60 minutes after the call has ended.
http://hugin.info/131801/R/1911453/682012.pdf
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Globenewswire
--- End of Message ---
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland
ISIN: CH0010532478;